Tempest Therapeutics Inc (FRA:3OS)

€ 0.704 0 (0%) Market Cap: 35.42 Mil Enterprise Value: 31.23 Mil PE Ratio: 0 PB Ratio: 2.05 GF Score: 39/100

Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call Transcript
Oct 11, 2023
Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Tempest Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 15, 2023
Tempest Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Tempest Therapeutics Inc To Discuss Phase 1b/2 Combination Study of TPST-1120 in First-Line HCC Data Call Transcript
Apr 28, 2023
Tempest Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Tempest Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 17, 2022
Tempest Therapeutics Inc At ASCO Call Transcript
Jun 05, 2022
Millendo Therapeutics Inc And Tempest Therapeutics Inc Merger - M&A Call Transcript
Mar 29, 2021

Tempest Therapeutics Inc At ASCO Call Transcript

Jun 05, 2022 / 11:30AM GMT

Transcript

Stephen R. Brady

Tempest Therapeutics, Inc. - CEO & Director

Good morning, everyone. I'm Steve Brady, I'm the CEO of Tempest Therapeutics. And this morning, I am joined by my colleague, Tom Dubensky, our President; Sam Whiting, our Chief Medical Officer; Anne Moon, who heads up Product and Project Development. And Nick Maestas, hand up, thanks Nick, who is the Vice President of Finance and Strategy. We are really fortunate this morning to be joined by a group of distinguished thought leaders. They're the real reason you're here not to listen to any of the Tempest folks. First, Mark Yarchoan from Hopkins. He's going to be speaking on Tuesday about our lead clinical program, TPST-1120 PPAR-alpha antagonist.

Just note there, this is our first clinical data that Tempest has presented, and then he's going to hand the phone off to Susanna Ulahannan from the University of Oklahoma. She's going to be speaking about our second clinical program, TPST-1495. And then finally, Jason Luke from UPMC is going to -- sorry, University of Pittsburgh School of Medicine is going to be talking about our TREX1

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.